Four heart failure drugs linked to fewer deaths in older adults
Thirty-day mortality was 2.9% among older patients discharged on all four recommended drug types, versus 19.1% among those prescribed three or fewer.
Limit: Frailty could influence prescribing and survival, exaggerating the apparent benefit of full treatment
Edited by Boris Djordjevic · AgingResearch.News
An observational study examined registry records for 1,878 adults aged 70 or older hospitalized with worsening heart failure and reduced heart pumping ability. Their average age was 77.7 years. Researchers compared patients prescribed all four recommended types of heart failure drugs at discharge with those prescribed three or fewer. The records covered January 2022 through July 2025.
The 30-day mortality analysis included 1,868 patients. Deaths occurred in 35 of 1,197 patients (2.9%) prescribed all four types, versus 128 of 671 (19.1%) prescribed fewer. Incomplete therapy remained associated with higher mortality after researchers adjusted for differences in recorded patient characteristics.
Why it matters
Older adults with heart failure are often underrepresented in clinical trials. These findings suggest that age alone should not be a barrier to optimizing recommended medicines after hospitalization.
Caveats
This observational study cannot determine whether the drugs caused the difference; other patient differences may have influenced prescribing and survival. The conference abstract covered adults aged 70 or older with reduced heart pumping ability and did not report adverse-event data.
The paper
Foundation Cardiovascular of Colombia
ESC Congress 2026 Abstract, Oct 26, 2026
Presented at ESC Congress 2026
